English
Language31 languages
EnglishEnglishDeutschGermanالعربيةArabicFrançaisFrenchEspañolSpanishPortuguês (Brasil)Brazilian PortugueseItalianoItalian日本語Japanese한국어KoreanРусскийRussianTürkçeTurkishفارسیPersian (Farsi)עבריתHebrewҚазақшаKazakhPolskiPolishNederlandsDutchRomânăRomanianČeštinaCzechΕλληνικάGreekMagyarHungarianBahasa IndonesiaIndonesianहिन्दीHindiاردوUrduBahasa MelayuMalayไทยThaiУкраїнськаUkrainianO‘zbekchaUzbekTiếng ViệtVietnamese繁體中文Traditional ChineseDanskDanishSvenskaSwedish

Supported languages are prioritized from the country mix of past inquiries. If you would like another language, please send us feedback.

Recent Confirmed OrdersLast 7 days
Australia2 gTirzepatide 100 mg · CagriSema 20 mg · BPC-157 10 mg · TB-500 5 mg · Melanotan II 10 mg · PT-141 10 mg · Bacteriostatic Water 3 ml
View all

Metabolic and incretin research

Semaglutide

Lipidated GLP-1 analog · analytical and metabolic research reagent

≥ 99.0% · target, verify batch COACAS 910463-68-2RUO
Research statusApproved active in named finished drugs; RUO bulk reagent here reference context · supplied material is RUO
Supplied form31-residue peptide (GLP-1 receptor agonist analog, fatty-acid acylated)
Lead time10–18 days
Semaglutide — White lyophilized powder
Semaglutide — White lyophilized powder · Representative packaging image · verify the ordered lot
Representative packaging image · verify the ordered lot

Decision summary

Key benefits

  • Research uses include GLP-1 receptor pharmacology, analytical method development, impurity characterization and comparative metabolic-pathway studies
  • Clinical outcomes reported for approved finished products are literature context, not performance claims for this RUO lot.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS
910463-68-2
Formula
C187H291N45O59
Molecular weight
About 4113.6 Da
Appearance
White lyophilized powder
Purity
≥ 99.0% · target, verify batch COA
Storage
Store and ship according to the released-lot COA, SDS and stability statement for the exact supplied form. Storage conditions for branded pens or tablets do not define stability of a bulk peptide, lyophilizate or laboratory solution.
MOQ
On request
Lead time
10–18 days
PubChem CID 56843331

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Semaglutide

Semaglutide is a lipidated 31-residue GLP-1 receptor agonist analog and the active ingredient in several named FDA-approved finished medicines. Those approvals and clinical data apply to the respective finished products, formulations and labelled uses. The material described on this page is a separate RUO bulk reagent and is not established as sterile, bioequivalent or suitable for administration.

  • The current US label describes product-specific uses for named finished injections and tablets in weight management and cardiovascular risk reduction, and an accelerated-approval MASH indication for WEGOVY injection
  • For this RUO reagent, relevant laboratory topics include receptor pharmacology, analytical characterization, impurities and comparative peptide research; no therapeutic indication is claimed.

Mechanism context

The question the literature is testing

Semaglutide is a GLP-1 receptor agonist analog with an Aib substitution that reduces DPP-4 cleavage, a Lys-linked C18 fatty-diacid moiety that promotes albumin binding, and a Lys-to-Arg substitution that controls the acylation site. In approved finished products, GLP-1 receptor activation affects glucose-dependent insulin secretion, glucagon secretion, gastric emptying and appetite. These pharmacology data do not establish formulation performance or clinical equivalence of an RUO bulk lot.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context
Routes reported in sources
SubcutaneousOral
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

  • This RUO bulk material is not an approved finished drug and is not established as sterile, bioequivalent or suitable for human or veterinary administration
  • FDA states that unapproved products sold falsely as research material for direct human use may be of unknown quality and harmful, and that semaglutide sodium and acetate are different active ingredients from the semaglutide used in approved drugs
  • Clinical safety information for branded products must not be used to qualify this lot.

Interactions reported in the literature

  • Finished-product labels describe clinically relevant interactions and precautions
  • They are not use instructions for this bulk reagent; laboratory mixtures require method-specific compatibility and interference assessment.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Semaglutide factory batch COAs

Semaglutide 2 mg Factory batch COA protected previewSemaglutide2 mg · WHJLP-SEMA2-260715-C
Semaglutide 5 mg Factory batch COA protected previewSemaglutide5 mg · WHJLP-SEMA5-260715-C
Semaglutide 10 mg Factory batch COA protected previewSemaglutide10 mg · WHJLP-SEMA10-260715-C
Semaglutide 15 mg Factory batch COA protected previewSemaglutide15 mg · WHJLP-SEMA15-260714-B
Semaglutide 20 mg Factory batch COA protected previewSemaglutide20 mg · WHJLP-SEMA20-260714-B
Semaglutide 30 mg Factory batch COA protected previewSemaglutide30 mg · WHJLP-SEMA30-260714-B
Semaglutide 50 mg Factory batch COA protected previewSemaglutide50 mg · WHJLP-SEMA50-260713-B
Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

  • Qualify the exact modified sequence, terminal state, lipid linker, supplied form and counterions
  • Review intact mass, a defined chromatographic method and impurity profile, peptide-content or assay basis, water, residual solvents, aggregates where relevant and released-lot storage
  • HPLC area purity alone does not establish content, identity, sterility or equivalence to an approved medicine.
Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack
SEMAG-02MG2 mg10 vials
SEMAG-05MG5 mg10 vials
SEMAG-10MG10 mg10 vials
SEMAG-15MG15 mg10 vials
SEMAG-20MG20 mg10 vials
SEMAG-30MG30 mg10 vials
SEMAG-50MG50 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Store and ship according to the released-lot COA, SDS and stability statement for the exact supplied form. Storage conditions for branded pens or tablets do not define stability of a bulk peptide, lyophilizate or laboratory solution.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

  • The current FDA prescribing information revised June 2026 documents WEGOVY injection and tablets as approved finished products. The tablet NDA was approved December 22, 2025; the label assigns weight-management and cardiovascular-risk indications to the tablets, while the accelerated-approval MASH indication applies to the injection. This label context does not qualify an independently supplied RUO bulk lot.
  • Wharton S, et al. N Engl J Med. 2025;393:1077-1087. PMID 40934115, DOI 10.1056/NEJMoa2500969, OASIS 4. In 307 randomized adults, oral semaglutide 25 mg or placebo was studied for 64 weeks. The treatment-policy estimand was -13.6% versus -2.2% body-weight change; the trial-product estimand was approximately -16.6% versus -2.7%. These are different analyses of one finished-product trial, not conflicting values or evidence for this RUO lot.
  • Lincoff AM, et al. N Engl J Med. 2023;389:2221-2232. PMID 37952131, DOI 10.1056/NEJMoa2307563, SELECT. Among 17,604 participants with established cardiovascular disease and overweight or obesity but without diabetes, the primary event hazard ratio was 0.80 (95% CI 0.72-0.90) over a mean 39.8-month follow-up. Trial-product discontinuation due to adverse events was 16.6% with semaglutide and 8.2% with placebo, mainly because of gastrointestinal disorders.
  • Garvey WT, et al. Nat Med. 2022;28:2083-2091. PMID 36216945, DOI 10.1038/s41591-022-02026-4, STEP 5. In 304 randomized participants, mean body-weight change at 104 weeks was -15.2% with semaglutide and -2.6% with placebo; gastrointestinal adverse events were reported in 82.2% and 53.9%, respectively. The results describe a named clinical-trial regimen, not bulk-reagent performance.
  • FDA proposed on April 30, 2026 not to include semaglutide, tirzepatide or liraglutide on the 503B Bulks List after finding insufficient evidence of clinical need for outsourcing facilities to compound them from bulk substances. A Federal Register notice extended the public-comment deadline to July 30, 2026. A proposal and comment period are not a final listing decision, and neither establishes approval or suitability of this RUO lot.
  1. 01

    Once-Weekly Semaglutide in Adults with Overweight or Obesity

    New England Journal of Medicine · 2021 · peer-reviewed original research (randomized controlled trial)

    Open source
  2. 02

    Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity

    New England Journal of Medicine · 2025 · peer-reviewed original research (randomized controlled trial)

    Open source
  3. 03

    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

    New England Journal of Medicine · 2023 · peer-reviewed original research (randomized controlled trial)

    Open source
  4. 04

    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    New England Journal of Medicine · 2016 · peer-reviewed original research (randomized controlled trial)

    Open source
  5. 05

    Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    New England Journal of Medicine · 2019 · peer-reviewed original research (randomized controlled trial)

    Open source
  6. 06

    Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis

    New England Journal of Medicine · 2025 · peer-reviewed original research (randomized controlled trial, planned interim analysis)

    Open source
  7. 07

    Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

    Nature Medicine · 2024 · peer-reviewed original research (secondary/subgroup analysis of RCT)

    Open source
  8. 08

    Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review

    International Journal of Molecular Sciences · 2024 · systematic literature review

    Open source

Product FAQ

Questions buyers ask about Semaglutide

What are Semaglutide's reference identity values?+

The commonly cited free-compound reference is CAS 910463-68-2, PubChem CID 56843331, formula C₁₈₇H₂₉₁N₄₅O₅₉ and average molecular weight about 4113.6 Da. Because the molecule is sequence- and linker-defined, the batch record should also identify the modified sequence, lipid linker, terminal state, supplied form and counterions.

What documentation should be agreed before qualifying a Semaglutide lot?+

Define the required COA before ordering: exact modified sequence and supplied form, intact mass, chromatographic method and impurity profile, peptide-content or assay basis, water, residual solvents, counterions and storage conditions supported for the released lot. Request orthogonal identity, aggregate, endotoxin, bioburden, sterility or solution-stability testing only when required by the intended laboratory workflow and confirm availability in writing.

Related research materials

Compare adjacent molecules and documentation needs.

Full catalog
Metabolic and incretin research

Tirzepatide

GIP / GLP-1 dual receptor agonist · 39-mer metabolic research peptide

Purity
Target ≥ 99.0% · Batch COA
CAS
2023788-19-2
Latest batch COA available on request
Metabolic and incretin research

Retatrutide

GIP / GLP-1 / glucagon tri-agonist · 39-mer metabolic research peptide

Purity
Target ≥ 99.0% · Batch COA
CAS
2381089-83-2
Latest batch COA available on request
Metabolic and incretin research

Cagrilintide

Long-acting lipidated amylin analogue research reference

Purity
Lot-specific · Batch COA
CAS
1415456-99-3
Latest batch COA available on request
Metabolic and incretin research

Liraglutide

GLP-1 receptor agonist · 31-mer metabolic reference standard

Purity
Target ≥ 99.0% · Batch COA
CAS
204656-20-2
Latest batch COA available on request